Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer
Trial Parameters
Brief Summary
The purpose of this study is to compare the efficacy and safety of nab-paclitaxel with solvent-based taxanes as first-line treatment for patients with advanced primary epithelial ovarian cancer (EOC), primary peritoneal carcinoma or fallopian tube carcinoma.
Eligibility Criteria
Inclusion Criteria: 1. Epithelial ovarian cancer/tubal cancer/peritoneal cancer was diagnosed by histopathology or hydroexfoliation cytopathology of the chest and abdomen, and was classified as stage III-IV according to FIGO（International Federation of Gynecology and Obstetrics）stage 2. Physical condition Eastern Cooperative Oncology Group PS score: 0-2 points 3. Participants who had not participated in other drug clinical trials within 4 weeks prior to enrollment 4. Written informed consent 5. Expected survival ≥6 months 6. The disease met the criteria for Efficacy Evaluation of solid tumors (RECIST 1.1) 7. Be able to comply with outpatient treatment, laboratory monitoring, and necessary clinical visits during study participation. Exclusion Criteria: 1. Patients with low malignant potential ovarian tumors; 2. Other malignant tumors within the previous 5 years, except for cured cervical carcinoma in situ and non-melanoma skin cancer; 3. Patients who have previously received chemotherap